Thermo Fisher Scientific at EACR25

Jose C Machado (JCM) is vice-president of the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), where he is also Department Chair. He is Associate Professor in the Faculty of Medicine of Porto. His research interest stands in the area of molecular genetics of cancer, and cancer immunology. He is internationally best known for his research in the area of Helicobacter pylori-related gastric carcinoma. The scientific question that drives his research group is how is genetic information transferred between cancer cells, and how does that transference impact on the heterogeneity, diversity and plasticity of cancer cells. He has have been awarded research projects by the Portuguese Foundation for Science and Technology, by the Portuguese Agency for Innovation, by the Portuguese Ministry of Health, by the European Union, and several other funding agencies. He is also the coordinator of the Molecular Pathology laboratory of IPATIMUP. This laboratory is one of the reference laboratories in Portugal for the detection of clinically actionable cancer-associated mutations. It is also one of the reference labs for the genetic diagnosis of hereditary cancer syndromes.

Noel FCC de Miranda is assistant professor at the Leiden University Medical Center and group leader of the Immunogenetics lab at the department of Pathology. His research group is studying the interactions between immune cells and cancer, particularly in colorectal and pancreatic cancers, with the aim of developing novel immunotherapies for advanced cancer patients. The lab has been focusing on designing neo-antigen-targeted therapies for tumors with low mutation burden and on the discovery of novel immune cell subsets with anti-cancer properties. Noel de Miranda his a recipient of an AACR fellowship, a VENI award (Dutch Organization for Scientific Research), and a Dutch Cancer Society Young Investigator Award.

[description goes here]

Dr. Godsey has an extensive background (30+ years) in Technology Discovery, Product Development and general management in the infectious disease and cancer diagnostic industry. He joined Thermo Fisher Scientific in 2015 as the Clinical Sequencing Division was established. He is responsible for all Technology Development, Assay Development, Bioinformatics and Instrument Development related to Next Generation Sequencing at 7 sites located within the US, including the division’s CLIA laboratory. Dr. Godsey’s Team gained FDA and PMDA approval of the first multi-variant, multi-drug NGS CDx for NSCLC, the Oncomine Dx Target Test. Prior the joining Thermo Fisher Scientific, Dr. Godsey held a number of senior executive R&D positions at: Roche Tissue Diagnostics (Ventana Medical Systems), Qiagen (formerly Digene), Veridex (JNJ), Gen-Probe, and Dade Behring/MicroScan. He also has 7 years of general management experience as the Global Product Line General Manager for Dade/MicroScan and the President/COO of Thermogenesis Inc, a medical device company specializing in serving the blood transfusion industry.

Dr. Godsey’s R&D accomplishments have focused primarily on cancer diagnostics for the last 15 years, creating Roche Tissue Diagnostics companion diagnostic capability, where his team developed one of the first PD-L1 IHC biomarkers for checkpoint inhibitor therapy. At Digene, Dr. Godsey developed the first developing country HPV screening test, CareHPV, for cervical cancer. At Veridex, he launched the Cell Search System for screening CTC’s (circulating tumor cells), still the only FDA approved platform with this indication.

At Gen-Probe, Dr. Godsey developed of the industry’s first FDA approved, fully automated nucleic acid testing-based blood screening system/tests for HIV, HCV, HBV and West Nile Virus, STD testing (CT/GC), Prostate Cancer diagnostic (PCA3 Assay) and HPV Testing (Aptima HPV) on the TIGRIS System. Today, the Procleix Blood Screening System still screens >50% the global transfused blood supply. At Dade Behring/MicroScan, as head of R&D, Dr. Godsey led the development of the industry’s first FDA approved automated clinical microbiology test system.